Regular
NAV (05-Sep-24)
Returns (Since Inception)
Fund Size
₹64 Cr
Expense Ratio
0.93%
ISIN
INF109KC18L6
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
15 Dec 2022
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+50.83%
— (Cat Avg.)
Since Inception
+39.57%
— (Cat Avg.)
Equity | ₹63.49 Cr | 99.88% |
Others | ₹0.08 Cr | 0.12% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹15.69 Cr | 24.69% |
Dr Reddy's Laboratories Ltd | Equity | ₹6.95 Cr | 10.93% |
Cipla Ltd | Equity | ₹6.85 Cr | 10.78% |
Divi's Laboratories Ltd | Equity | ₹5.3 Cr | 8.34% |
Lupin Ltd | Equity | ₹3.91 Cr | 6.14% |
Aurobindo Pharma Ltd | Equity | ₹3.41 Cr | 5.36% |
Zydus Lifesciences Ltd | Equity | ₹2.65 Cr | 4.17% |
Torrent Pharmaceuticals Ltd | Equity | ₹2.45 Cr | 3.85% |
Alkem Laboratories Ltd | Equity | ₹2.25 Cr | 3.54% |
Glenmark Pharmaceuticals Ltd | Equity | ₹1.86 Cr | 2.92% |
Mankind Pharma Ltd | Equity | ₹1.58 Cr | 2.49% |
Laurus Labs Ltd | Equity | ₹1.54 Cr | 2.43% |
Ipca Laboratories Ltd | Equity | ₹1.49 Cr | 2.34% |
Biocon Ltd | Equity | ₹1.36 Cr | 2.14% |
Abbott India Ltd | Equity | ₹1.27 Cr | 2.00% |
Gland Pharma Ltd | Equity | ₹1.25 Cr | 1.97% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.16 Cr | 1.83% |
Treps | Cash - Repurchase Agreement | ₹1.11 Cr | 1.74% |
Natco Pharma Ltd | Equity | ₹1.05 Cr | 1.64% |
Net Current Assets | Cash | ₹-1.03 Cr | 1.62% |
Granules India Ltd | Equity | ₹0.72 Cr | 1.14% |
Sanofi India Ltd | Equity | ₹0.5 Cr | 0.79% |
Sanofi Consumer He | Equity | ₹0.24 Cr | 0.38% |
Large Cap Stocks
61.09%
Mid Cap Stocks
30.59%
Small Cap Stocks
7.82%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹63.24 Cr | 99.50% |
Standard Deviation
This fund
--
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Since December 2022
Since February 2024
ISIN | INF109KC18L6 | Expense Ratio | 0.93% | Exit Load | No Charges | Fund Size | ₹64 Cr | Age | 15 Dec 2022 | Lumpsum Minimum | ₹1,000 | Fund Status | Open Ended Investment Company | Benchmark | Nifty Pharma TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Dividends are added to the investor’s income and taxed according to their respective tax slabs. Additionally, if an investors dividend income exceeds INR 5,000 in a financial year, the fund house deducts a 10% Tax Deducted at Source (TDS) before distributing the dividend.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹539.42 Cr | 45.5% |
ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹539.42 Cr | 44.6% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹397.46 Cr | 61.6% |
SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹587.30 Cr | 42.9% |
DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1683.73 Cr | 39.1% |
SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1000.66 Cr | 49.6% |
SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹587.30 Cr | 43.7% |
ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹397.46 Cr | 62.6% |
DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1683.73 Cr | 39.9% |
SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹1000.66 Cr | 48.7% |
Total AUM
₹8,56,645 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk